VESATOLIMOD
Vesatolimod is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 3 | — | — | — | 6 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | 3 | 2 | — | — | 1 | 6 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 3 | 2 | — | — | 1 | 6 |
| Hepatitis b | D006509 | — | — | 2 | 2 | — | — | 1 | 5 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 2 | 2 | — | — | 1 | 5 |
| Chronic hepatitis | D006521 | — | K73.9 | — | 2 | — | — | 1 | 3 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | — | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | 1 | — | — | — | — | 1 |
| Herpesviridae infections | D006566 | EFO_0007309 | B00.4 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | VESATOLIMOD |
| INN | vesatolimod |
| Description | Vesatolimod (GS-9620) is an antiviral drug developed by Gilead Sciences, which acts as a potent and selective agonist of Toll-like receptor 7 (TLR7), a receptor involved in the regulation of the immune system. It is used to stimulate the immune system, which can increase its ability to combat chronic viral infections. Vesatolimod is in clinical trials to determine whether it is safe and effective in patients with Hepatitis B and HIV/AIDS, and has also shown activity against other viral diseases such as norovirus and enterovirus 71.
|
| Classification | Small molecule |
| Drug class | immunomodulators: immunomodulators, toll-like receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCOc1nc(N)c2c(n1)N(Cc1cccc(CN3CCCC3)c1)CC(=O)N2 |
Identifiers
| PDB | — |
| CAS-ID | 1228585-88-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2424780 |
| ChEBI ID | — |
| PubChem CID | 46241268 |
| DrugBank | DB12687 |
| UNII ID | O8M467C50G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 239 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use